Padmanabh Bhatt Biography and Net Worth

Senior Vice President, Chief Scientific Officer, Intellectual Property of Supernus Pharmaceuticals

Padmanabh P. Bhatt, Ph.D, has served as our Senior Vice President of Intellectual Property and Chief Scientific Officer since March 2012. Prior to that, he served as our Vice President of Pharmaceutical Sciences beginning in 2005. From 2003 to 2005, Dr. Bhatt was Vice President of Advanced Drug Delivery at Shire Laboratories, Inc. From 2001 to 2003, Dr. Bhatt served as Vice President of Research and Development and Chief Technology Officer at Point Biomedical Corporation. From 1996 to 2001, he served at ALZA (now a Johnson & Johnson company) in various positions, from Product Development Manager to Director of Technical Development. Prior to that time, Dr. Bhatt held positions as Research Specialist and Group Leader of Novel Drug Delivery at Dow Corning Corporation (from 1992 to 1996) and Senior Scientist at Hercon Laboratories (from 1989 to 1992).
Dr. Bhatt earned his B.Pharm and M.Pharm degrees from the University of Bombay, India. He also holds M.S. and Ph.D. degrees in Pharmaceutical Chemistry from the University of Kansas.

What is Padmanabh P. Bhatt's net worth?: The estimated net worth of Padmanabh P. Bhatt is at least $457.72 thousand as of February 4th, 2025. Dr. Bhatt owns 10,149 shares of Supernus Pharmaceuticals stock worth more than $457,720 as of December 4th. This net worth approximation does not reflect any other assets that Dr. Bhatt may own. Additionally, Dr. Bhatt receives a salary of $594,140.00 as Senior Vice President, Chief Scientific Officer, Intellectual Property at Supernus Pharmaceuticals. Learn More about Padmanabh P. Bhatt's net worth.
How old is Padmanabh P. Bhatt?: Dr. Bhatt is currently 67 years old. There are 6 older executives and no younger executives at Supernus Pharmaceuticals. The oldest executive at Supernus Pharmaceuticals is Ms. Tami T. Martin Esq., R.N., Senior Vice President of Regulatory Affairs, who is 69 years old. Learn More on Padmanabh P. Bhatt's age.
What is Padmanabh P. Bhatt's salary?: As the Senior Vice President, Chief Scientific Officer, Intellectual Property of Supernus Pharmaceuticals, Inc., Dr. Bhatt earns $594,140.00 per year. There are 3 executives that earn more than Dr. Bhatt. The highest earning executive at Supernus Pharmaceuticals is Mr. Jack A. Khattar, Founder, President, CEO, Secretary & Director, who commands a salary of $1,630,000.00 per year. Learn More on Padmanabh P. Bhatt's salary.
How do I contact Padmanabh P. Bhatt?: The corporate mailing address for Dr. Bhatt and other Supernus Pharmaceuticals executives is 1550 E GUDE DR, ROCKVILLE MD, 20850. Supernus Pharmaceuticals can also be reached via phone at (301) 838-2500 and via email at [email protected]. Learn More on Padmanabh P. Bhatt's contact information.
Has Padmanabh P. Bhatt been buying or selling shares of Supernus Pharmaceuticals?: Padmanabh P. Bhatt has not been actively trading shares of Supernus Pharmaceuticals in the last ninety days. Most recently, Padmanabh P. Bhatt sold 9,477 shares of the business's stock in a transaction on Tuesday, February 4th. The shares were sold at an average price of $39.70, for a transaction totalling $376,236.90. Following the completion of the sale, the vice president now directly owns 10,149 shares of the company's stock, valued at $402,915.30. Learn More on Padmanabh P. Bhatt's trading history.
Who are Supernus Pharmaceuticals' active insiders?: Supernus Pharmaceuticals' insider roster includes Padmanabh Bhatt (Senior Vice President, Chief Scientific Officer, Intellectual Property), Timothy Dec (CFO), Georges Gemayel (Director), Frederick Hudson (Director), Jack Khattar (President and Chief Executive Officer, Director), Frank Mottola (SVP, GMP Operations, IT and Regulatory Affairs), Jonathan Rubin (Senior Vice President, Chief Medical Officer, Research & Development), and Bethany Sensenig (Director). Learn More on Supernus Pharmaceuticals' active insiders.
Are insiders buying or selling shares of Supernus Pharmaceuticals?: In the last twelve months, insiders at the specialty pharmaceutical company sold shares 16 times. They sold a total of 373,845 shares worth more than $16,830,854.81. The most recent insider tranaction occured on October, 9th when CEO Jack A Khattar sold 59,900 shares worth more than $3,029,143.00. Insiders at Supernus Pharmaceuticals own 8.8% of the company. Learn More about insider trades at Supernus Pharmaceuticals.
Information on this page was last updated on 10/9/2025.

Padmanabh P. Bhatt Insider Trading History at Supernus Pharmaceuticals

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
2/4/2025	Sell	9,477	$39.70	$376,236.90	10,149
1/28/2025	Sell	700	$39.62	$27,734.00	10,149
3/21/2024	Sell	14,491	$35.31	$511,677.21	8,570
3/19/2024	Sell	12,364	$35.31	$436,572.84	8,570
3/12/2024	Sell	3,884	$32.99	$128,133.16	8,570
2/26/2024	Sell	5,000	$30.21	$151,050.00	8,570
1/17/2023	Sell	4,826	$39.92	$192,653.92	1,644
1/6/2023	Sell	174	$39.90	$6,942.60	1,644
12/1/2022	Sell	5,000	$37.48	$187,400.00	1,644
11/11/2022	Sell	6,800	$34.95	$237,660.00	1,644
11/9/2022	Sell	700	$34.97	$24,479.00	1,644
6/29/2018	Sell	7,795	$59.92	$467,076.40	7,795
6/21/2018	Sell	7,205	$60.00	$432,300.00	14,705
5/15/2018	Sell	7,868	$57.93	$455,793.24	7,868
5/11/2018	Sell	67,132	$53.11	$3,565,380.52	32,500
1/22/2018	Sell	20,000	$48.04	$960,800.00	32,500
1/17/2018	Sell	20,000	$44.98	$899,600.00	32,500
9/8/2017	Sell	5,000	$49.86	$249,300.00	12,500
8/16/2017	Sell	3,709	$45.23	$167,758.07	17,500
7/12/2017	Sell	3,735	$44.90	$167,701.50	21,209
6/23/2017	Sell	2,556	$44.90	$114,764.40	24,944
6/2/2017	Sell	10,000	$39.86	$398,600.00	27,500
5/26/2017	Sell	2,500	$35.90	$89,750.00	37,500
5/25/2017	Sell	5,500	$34.90	$191,950.00	43,887
4/24/2017	Sell	11,806	$32.59	$384,757.54	45,500
4/11/2016	Sell	30,762	$16.49	$507,265.38	57,306
12/9/2015	Sell	14,238	$14.90	$212,146.20	88,068
11/4/2015	Sell	5,000	$19.90	$99,500.00	102,306

Padmanabh P. Bhatt Buying and Selling Activity at Supernus Pharmaceuticals

Supernus Pharmaceuticals Company Overview

Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age. It also offers comprise Qelbree, a novel non-stimulant indicated for the treatment of attention-deficit hyperactivity disorder (ADHD) in adults and pediatric patients 6 years and older; APOKYN for the acute intermittent treatment of hypomobility or off episodes in patients with advanced Parkinson's Disease (PD); XADAGO for treating levodopa/carbidopa in patients with PD experiencing off episodes; MYOBLOC, a Type B toxin product indicated for the treatment of cervical dystonia and sialorrhea in adults; GOCOVRI for the treatment of dyskinesia in patients with PD; and Osmolex ER for the treatment of Parkinson's disease and drug-induced extrapyramidal reaction in adult patients. In addition, the company's product candidates include SPN-830, a late-stage drug/device combination product candidate for the treatment of off episodes in PD patients; SPN-817, a novel first-in-class selective acetylcholinesterase inhibitor, which is in Phase II clinical trials for the treatment of epilepsy; SPN-820, a product candidate in Phase II clinical trials for treating resistant depression; SPN-443, a preclinical product for the treatment of ADHD/CNS; and SPN-446 for narcolepsy and SPN-448 for the treatment of CNS which is in discovery stage. It markets and sells its products through pharmaceutical wholesalers, specialty pharmacies, and distributors. Supernus Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Rockville, Maryland.

Today's Range

Now: $45.10

$44.28

$45.10

50 Day Range

MA: $48.40

$44.12

$57.00

2 Week Range

Now: $45.10

$29.16

$57.65

Volume

493,657 shs

Average Volume

807,434 shs

Market Capitalization

$2.59 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.71

Padmanabh Bhatt Biography and Net Worth

What is Padmanabh P. Bhatt's net worth?

How old is Padmanabh P. Bhatt?

What is Padmanabh P. Bhatt's salary?

How do I contact Padmanabh P. Bhatt?

Has Padmanabh P. Bhatt been buying or selling shares of Supernus Pharmaceuticals?

Who are Supernus Pharmaceuticals' active insiders?

Are insiders buying or selling shares of Supernus Pharmaceuticals?